Specific Susceptibility to COVID-19 in Adults with Down Syndrome

NeuroMolecular Medicine - Tập 23 - Trang 561-571 - 2021
Tomer Illouz1,2, Arya Biragyn3, Milana Frenkel-Morgenstern4, Orly Weissberg4, Alessandro Gorohovski4, Eugene Merzon5, Ilan Green5, Florencia Iulita6,7,8,9, Lisi Flores-Aguilar10, Mara Dierssen11,12,13, Ilario De Toma14,15,16, Hefziba Lifshitz17, Stylianos E. Antonarakis18,19,20, Eugene Yu21,22, Yann Herault23, Marie-Claude Potier24, Alexandra Botté24, Randall Roper25, Benjamin Sredni26, Ronit Sarid24, Jacqueline London27, William Mobley28, Andre Strydom29,30, Eitan Okun1,2,26
1The Leslie and Susan Gonda Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat-Gan, Israel
2The Paul Feder Laboratory On Alzheimer’s Disease Research, Bar-Ilan University, Ramat-Gan, Israel
3Laboratory of Molecular Biology and Immunology, NIA, Baltimore, USA
4Cancer Genomics and BioComputing of Complex Diseases Lab, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
5Leumit Health Services, Department of Family Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel
6Sant Pau Memory Unit, Department of Neurology, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain
7Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
8Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain
9Alzheimer-Down Unit, Fundación Catalana Síndrome de Down, Barcelona, Spain
10Department of Anatomy and Cell Biology, McGill University, Montreal, Canada
11Center for Genomic Regulation, The Barcelona Institute for Science and Technology, Barcelona, Spain
12University Pompeu Fabra, Barcelona, Spain
13Biomedical Research Networking Center for Rare Diseases (CIBERER), Barcelona, Spain
14Cellular & Systems Neurobiology, Systems Biology Program, The Barcelona Institute of Science and Technology, Centre for Genomic Regulation (CRG), Barcelona, Spain
15Universitat Pompeu Fabra (UPF), Barcelona, Spain
16Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
17School of Education, Bar Ilan University, Ramat Gan, Israel
18Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland
19Medigenome, Swiss Institute of Genomic Medicine, Geneva, Switzerland
20iGE3 Institute of Genetics and Genomics of Geneva, Geneva, Switzerland
21The Children’s Guild Foundation Down Syndrome Research Program, Genetics and Genomics Program and Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, USA
22Genetics, Genomics and Bioinformatics Program, State University of New York At Buffalo, Buffalo, USA
23Université de Strasbourg, CNRS, INSERM, Institut de Génétique Biologie Moléculaire Et Cellulaire, IGBMC–UMR, Cedex, France
24Paris Brain Institute (ICM), CNRS UMR7225, INSERM U1127, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France
25Department of Biology, Indiana University Purdue University Indianapolis, Indianapolis, USA
26The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
27Université de Paris, BFA, UMR 8251, CNRS, Paris, France
28Department of Neurosciences, University of California, San Diego, USA
29Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry Psychology and Neuroscience, King’s College London, London, UK
30South London and Maudsley NHS Foundation Trust, London, UK

Tóm tắt

The current SARS-CoV-2 outbreak, which causes COVID-19, is particularly devastating for individuals with chronic medical conditions, in particular those with Down Syndrome (DS) who often exhibit a higher prevalence of respiratory tract infections, immune dysregulation and potential complications. The incidence of Alzheimer’s disease (AD) is much higher in DS than in the general population, possibly increasing further the risk of COVID-19 infection and its complications. Here we provide a biological overview with regard to specific susceptibility of individuals with DS to SARS-CoV-2 infection as well as data from a recent survey on the prevalence of COVID-19 among them. We see an urgent need to protect people with DS, especially those with AD, from COVID-19 and future pandemics and focus on developing protective measures, which also include interventions by health systems worldwide for reducing the negative social effects of long-term isolation and increased periods of hospitalization.

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

NeuroMolecular Medicine

Tập 23

561-571

Thông tin tác giả